Hanol Biopharma Reports Strong Financial Performance
Hanol Biopharma (009420) has announced its financial results for the third quarter, showcasing a significant increase in profitability. The company's cumulative revenue for the year reached KRW 1,242 billion, with a notable 2.2% decline in Q3 revenue compared to the previous year. However, the operating profit witnessed a remarkable surge of 265.1%.
Hanol Biopharma disclosed its consolidated financial figures for the third quarter, revealing a revenue of KRW 399 billion, an operating profit of KRW 13 billion, and a net profit of KRW 31 billion. The net profit experienced a substantial growth of 924.2% year-over-year. During the same period, R&D expenses decreased by 53.7%, dropping from KRW 48 billion to KRW 22 billion.
In the pharmaceutical business, the probiotic 'Biotap' achieved its highest quarterly sales. Biotap's Q3 revenue totaled KRW 76 billion, while its cumulative revenue increased by 31% year-over-year, reaching KRW 223 billion. The non-absorbable antibiotic 'Normix' and the prostate cancer treatment 'Eligard' also contributed with cumulative revenues of KRW 150 billion and KRW 131 billion, respectively.
The company's performance highlights its focus on commercialization and the successful development of key drugs. With the approval of 'Vatoklimab' in China and the upcoming sequential announcement of clinical trial results for its core drugs, Hanol Biopharma is poised for further growth.
Financial Outlook: Pharmaceutical Sector
Sales Growth and Product Expansion
The sales of hair loss treatment medications have seen a notable increase. The drug 'Hairgro', containing the active ingredient finasteride, broke through with over 25 million units sold in September. This month, the company launched 'Pangro Liquid 5%', a topical treatment featuring minoxidil, further expanding its product range.
New Drug Development and Global Reach
In the realm of novel drug development, 'Vatolizumab', an FcRn antibody therapy, gained approval as a systemic treatment for myasthenia gravis in China this month. This marks a significant milestone as Hanol Biopharma's first self-developed drug to receive approval overseas.
The next-generation FcRn antibody therapy, 'Imeroprubat (HL161ANS)', is currently undergoing clinical development with its global partner, Immunovant, for five indications. These include Graves' disease, refractory rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjögren's syndrome.
Upcoming Milestones
The latter half of this year is anticipated to bring the top-line announcement of key results from the registrational trial for refractory rheumatoid arthritis. Subsequently, in 2027, major clinical outcomes for Graves' disease and myasthenia gravis are expected, followed by Sjögren's syndrome and chronic inflammatory demyelinating polyneuropathy in 2028.
HanAll Biopharma: Expanding Growth Prospects and Clinical Milestones
A spokesperson for HanAll Biopharma commented, "While maintaining the growth momentum of our existing core products, we are continuously introducing new items to broaden the growth foundation of our pharmaceutical business. We anticipate that the competitive edge and scalability of our key pipelines will become increasingly evident as we sequentially announce major clinical results in 2027 and 2028, following this year's announcements."
*HanAll Biopharma's Biologics Pipeline Progress (as of October 28, 2026). Source: HanAll Biopharma*
